Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Phentermine
Drug ID BADD_D01756
Description Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine.[A174370] Phentermine has not been reported an addictive potential which allows this agent to be classified under the Schedule IV drugs (low abuse potential).[A174367] Phentermine was FDA approved for short-term weight management in 1959 and it became widely used in 1960. This initial product, formed by the combination of phentermine with [fenfluramine] and [dexfenfluramine] was discontinued after finding several reports of abnormal valves in nearly 30% of the consumers.[A174376, T403] Later on, phentermine was approved alone and in combination with topiramate in 2012 as a new alternative that required lower doses of phentermine to obtain the desired effect.[A174373]
Indications and Usage For the treatment and management of obesity.
Marketing Status Prescription; Discontinued
ATC Code A08AA01
DrugBank ID DB00191
KEGG ID D05458
MeSH ID D010645
PubChem ID 4771
TTD Drug ID D0U0RZ
NDC Product Code Not Available
Synonyms Phentermine | Duromine | Phentermine Hydrochloride | Hydrochloride, Phentermine | Adipex-P | Adipex P | AdipexP | Ionamine
Chemical Information
Molecular Formula C10H15N
CAS Registry Number 122-09-8
SMILES CC(C)(CC1=CC=CC=C1)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Renal vein thrombosis24.01.11.002; 20.01.07.0110.001234%Not Available
Restlessness19.11.02.002; 17.02.05.021--
Rhabdomyolysis15.05.05.0020.000193%
Sinus tachycardia02.03.03.0100.000987%
Subarachnoid haemorrhage17.08.01.010; 24.07.04.004; 12.01.10.0110.000644%Not Available
Swelling08.01.03.0150.000740%Not Available
Tachycardia02.03.02.0070.002221%Not Available
Tardive dyskinesia17.01.02.0120.000494%Not Available
Tension19.06.02.005--Not Available
Tremor17.01.06.0020.000740%
Urinary incontinence20.02.02.010; 17.05.01.0080.000494%
Urticaria23.04.02.001; 10.01.06.001--
Vertigo17.02.12.002; 04.04.01.0030.000494%
Vomiting07.01.07.0030.001974%
Weight increased13.15.01.0060.000740%
Tubulointerstitial nephritis20.05.02.0020.000494%Not Available
Emotional distress19.04.02.0080.000494%Not Available
Pneumomediastinum22.09.03.0040.000740%Not Available
Ejection fraction decreased13.14.02.0030.000494%
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Hypoperfusion24.06.02.0190.000740%Not Available
Spinal cord infarction24.04.06.018; 17.10.01.0090.000322%Not Available
Urine output decreased13.13.03.0010.000494%
Monoclonal gammopathy16.23.01.003; 01.14.01.0030.000740%Not Available
Libido disorder21.03.02.006; 19.08.03.004--Not Available
Cardiac valve disease02.07.02.001--Not Available
Erectile dysfunction21.03.01.007; 19.08.04.001--
Psychotic disorder19.03.01.002--
Bowel movement irregularity07.02.03.0030.000494%Not Available
Pulmonary arterial hypertension24.08.03.003; 22.06.01.002--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages